Tango Therapeutics, Inc.
TNGX
Rang in Aktien
#4534
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Aktienkurs
$27.18
Zuletzt synchronisiert: 2026-07-31
Marktkapitalisierung
$3.38B
Veränderung (1 Tag)
-1.41%
Veränderung (1 Jahr)
197.05%
Land
US
Handel Tango Therapeutics, Inc. (TNGX)
Kategorie
Healthcare
EPS für Tango Therapeutics, Inc. (TNGX)
EPS zum June 2026 TTM: $-0.85
Laut den aktuellen Finanzberichten und dem Aktienkurs von Tango Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-0.85. Am Ende des Jahres 2023 betrug das EPS $-1.08 ein Rückgang im Vergleich zu dem EPS von 2022, das $-1.23 betrug.
EPS-Verlauf von Tango Therapeutics, Inc. von 2019 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-0.85 | -28.57% |
| 2024 | $-1.19 | 10.19% |
| 2023 | $-1.08 | -12.20% |
| 2022 | $-1.23 | 30.85% |
| 2021 | $-0.94 | -41.98% |
| 2020 | $-1.62 | 3.18% |
| 2019 | $-1.57 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -2,137.65% |
US
|
|
| $-7.98 | 838.82% |
US
|
|
| $-5.29 | 522.35% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,363.53% |
NL
|
